Damien Urban

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Roy S. Herbst, Yi‐Long Wu, Thomas John et al. · Journal of Clinical Oncology · 2023 · 389 citations · Full text

Medicine, Oncology, Pharmacology +17

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan et al. · Journal of Thoracic Oncology · 2018 · 220 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma

Benjamin Solomon, Richard J. Young, Mathias Bressel et al. · Cancer Immunology Research · 2018 · 127 citations · Full text

Life Sciences, Immunology, Oncology +14

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim et al. · Journal of Clinical Oncology · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +16

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study

Jair Bar, Gal Markel, Teodor Gottfried et al. · European Journal of Cancer · 2019 · 102 citations

Life Sciences, Immunology, Internal Medicine +12